Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2023 09:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
December 12, 2022 08:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
December 07, 2022 09:10 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
November 22, 2022 09:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Action to comply with continued listing requirements for Nasdaq Capital Market CARLSBAD, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics,...
November 15, 2022 07:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Q3 2022 FastPack ® sales increased approximately 25% year-over-yearCompany continues to execute on and advance core therapeutic programs CARLSBAD, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen...
October 19, 2022 09:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Fourth RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
October 18, 2022 09:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics to Present at LD Micro Main Event XV

CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
October 06, 2022 08:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium

CARLSBAD, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
September 14, 2022 17:02 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting

Posters include data regarding 1) mode of action, and 2) preclinical toxicology CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
August 18, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right